Measles, mumps, and rubella virus vaccine (M-M-R(TM)II): A review of 32 years of clinical and postma...
Measles, mumps, and rubella virus vaccine (M-M-R(TM)II): A review of 32 years of clinical and postmarketing experience
About this item
Full title
Author / Creator
Publisher
Kidlington: Elsevier Limited
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: Elsevier Limited
Subjects
More information
Scope and Contents
Contents
Highlights * The 32-year safety profile of M-M-R(TM)II is described using data from postmarketing surveillance. * Of ~575 million doses distributed, 17,536 AEs were voluntarily reported (30.5 AEs/1x106doses). * This review provides evidence that the vaccine is safe and well-tolerated.
Alternative Titles
Full title
Measles, mumps, and rubella virus vaccine (M-M-R(TM)II): A review of 32 years of clinical and postmarketing experience
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1625878299
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1625878299
Other Identifiers
ISSN
0264-410X
E-ISSN
1873-2518
DOI
10.1016/j.vaccine.2012.08.057
